Senzar Asset Management LLC Has Decreased Halozyme Therapeutics INC (HALO) Position as Stock Rose

Halozyme Therapeutics, Inc. (NASDAQ:HALO) LogoInvestors sentiment increased to 1.47 in 2019 Q2. Its up 0.03, from 1.44 in 2019Q1. It increased, as 16 investors sold HALO shares while 44 reduced holdings. 28 funds opened positions while 60 raised stakes. 105.70 million shares or 8.25% less from 115.20 million shares in 2019Q1 were reported. Strs Ohio, Ohio-based fund reported 70,100 shares. Pub Employees Retirement Association Of Colorado reported 26,722 shares. Vanguard Group Inc owns 0.01% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 13.30 million shares. Charles Schwab Investment Mngmt reported 885,353 shares stake. Barclays Public Limited Liability Corporation accumulated 106,988 shares. Marshall Wace Ltd Liability Partnership owns 513,083 shares for 0.07% of their portfolio. Hightower Advsr Limited Liability Corp holds 0% or 29,129 shares. First Republic Invest Management invested in 0% or 42,036 shares. The Wisconsin-based State Of Wisconsin Investment Board has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Axa holds 0.03% or 436,419 shares in its portfolio. Ubs Asset Mngmt Americas reported 116,933 shares or 0% of all its holdings. Legal And General Group Plc reported 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Private Advisor Grp Ltd Liability Corporation has invested 0% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Goldman Sachs accumulated 1.40 million shares or 0.01% of the stock. 131,350 were accumulated by Sei Invests Co.

Senzar Asset Management Llc decreased its stake in Halozyme Therapeutics Inc (HALO) by 6.29% based on its latest 2019Q2 regulatory filing with the SEC. Senzar Asset Management Llc sold 257,074 shares as the company’s stock rose 5.07% . The hedge fund held 3.83M shares of the health care company at the end of 2019Q2, valued at $66.53M, down from 4.09 million at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Halozyme Therapeutics Inc for a number of months, seems to be less bullish one the $2.35B market cap company. The stock increased 2.62% or $0.41 during the last trading session, reaching $16.05. About 1.38 million shares traded or 83.21% up from the average. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has declined 1.34% since October 12, 2018 and is downtrending. It has underperformed by 1.34% the S&P500.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on November, 5. They expect $-0.13 earnings per share, up 31.58 % or $0.06 from last year’s $-0.19 per share. After $-0.10 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 30.00 % negative EPS growth.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Seekingalpha.com which released: “ZAGG acquires HALO – Seeking Alpha” on January 03, 2019, also Globenewswire.com with their article: “HALO Labs: Building A Cannabis Concentrate & Oil Empire — CFN Media – GlobeNewswire” published on April 09, 2019, Prnewswire.com published: “Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology – PRNewswire” on July 12, 2019. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: Nasdaq.com and their article: “Health Care Sector Update for 01/10/2019: HALO,PRPO,CGIX – Nasdaq” published on January 10, 2019 as well as Nasdaq.com‘s news article titled: “Relationship Marketing as an Advisor Differentiator – Nasdaq” with publication date: September 06, 2019.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.